Thyrotropin deficiency after polonged high levels of plasma thyroid hormones. 1976

Berthezène, and B Chavrier, and J P Riou, and M Fournier, and R Mornex

In order to elucidate the mechanism of the Farquharson phenomenon, we studied the thyrotropin function in three groups of patients who had had high plasma levels of thyroid hormones for prolonged period of time : 3 patients (group A) had taken thyroid hormones for several years. One month after discontinuation of the treatment two of them were hypothyroid; in both of them plasma TSH did not increase after injection of TRH. Spontaneous recovery occured in those two patients respectively five and nineteen months after the end of the drug administration. One year after having stopped the treatment the third patient was apparently euthyroid; however, she was proved to have a complete TSH deficiency. Group B consisted of 27 patients who were studied after surgical ablation of toxic adenoma. Four of them were hypothyroid one to four months after surgery and had no response to TRH. Fifteen out of the 23 remaining patients were euthyroid but had such a lack of response to TRH from 5 days to one year after surgery. Group C consisted of forty three patients treated for Graves' disease and who had been euthyroid for at least one year following the treatment. Seven of them exhibited no or a subnormal response to TRH. Finally, thirteen patients (from groups A, B and C) who did not respond to TRH were given 10 mg TRH orally twice a day for two weeks. A normalization of the TRH test was then demonstrated in three patients and a partial recovery in three others. Thus, there is a frequent thyrotropin deficiency after prolonged high levels of plasma thyroid hormones which can disappear spontaneously or after chronic TRH administration.

UI MeSH Term Description Entries
D007037 Hypothyroidism A syndrome that results from abnormally low secretion of THYROID HORMONES from the THYROID GLAND, leading to a decrease in BASAL METABOLIC RATE. In its most severe form, there is accumulation of MUCOPOLYSACCHARIDES in the SKIN and EDEMA, known as MYXEDEMA. It may be primary or secondary due to other pituitary disease, or hypothalamic dysfunction. Central Hypothyroidism,Primary Hypothyroidism,Secondary Hypothyroidism,TSH Deficiency,Thyroid-Stimulating Hormone Deficiency,Central Hypothyroidisms,Deficiency, TSH,Deficiency, Thyroid-Stimulating Hormone,Hormone Deficiency, Thyroid-Stimulating,Hypothyroidism, Central,Hypothyroidism, Primary,Hypothyroidism, Secondary,Hypothyroidisms,Primary Hypothyroidisms,Secondary Hypothyroidisms,TSH Deficiencies,Thyroid Stimulating Hormone Deficiency,Thyroid-Stimulating Hormone Deficiencies
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006044 Goiter, Nodular An enlarged THYROID GLAND containing multiple nodules (THYROID NODULE), usually resulting from recurrent thyroid HYPERPLASIA and involution over many years to produce the irregular enlargement. Multinodular goiters may be nontoxic or may induce THYROTOXICOSIS. Nodular Goiter,Goiters, Nodular,Nodular Goiters
D006111 Graves Disease A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes (GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy). Basedow's Disease,Exophthalmic Goiter,Goiter, Exophthalmic,Graves' Disease,Basedow Disease,Hyperthyroidism, Autoimmune,Basedows Disease,Disease, Basedow,Disease, Basedow's,Disease, Graves,Disease, Graves',Exophthalmic Goiters,Goiters, Exophthalmic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Berthezène, and B Chavrier, and J P Riou, and M Fournier, and R Mornex
January 1983, Medicina,
Berthezène, and B Chavrier, and J P Riou, and M Fournier, and R Mornex
November 1957, The Journal of clinical endocrinology and metabolism,
Berthezène, and B Chavrier, and J P Riou, and M Fournier, and R Mornex
May 1984, Clinical endocrinology,
Berthezène, and B Chavrier, and J P Riou, and M Fournier, and R Mornex
January 1987, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology,
Berthezène, and B Chavrier, and J P Riou, and M Fournier, and R Mornex
January 1979, The Journal of clinical endocrinology and metabolism,
Berthezène, and B Chavrier, and J P Riou, and M Fournier, and R Mornex
June 1978, Biochemical and biophysical research communications,
Berthezène, and B Chavrier, and J P Riou, and M Fournier, and R Mornex
February 2011, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
Berthezène, and B Chavrier, and J P Riou, and M Fournier, and R Mornex
July 2004, Endocrine,
Berthezène, and B Chavrier, and J P Riou, and M Fournier, and R Mornex
February 1977, The Journal of clinical endocrinology and metabolism,
Berthezène, and B Chavrier, and J P Riou, and M Fournier, and R Mornex
May 1993, Pathologie-biologie,
Copied contents to your clipboard!